Anticancer nanomedicines have been proven effective in mitigating the side effects of
chemotherapeutic drugs. However, challenges remain in augmenting their therapeutic …

Phenotypic plasticity has emerged as a major contributor to intra-tumoral heterogeneity and
treatment resistance in cancer. Increasing evidence shows that glioblastoma (GBM) cells …

Glioblastoma (GBM), a highly lethal brain cancer, is notorious for immunosuppression, but
the mechanisms remain unclear. Here, we documented a temporospatial patterning of tumor …

Mapping tumor metabolic remodeling and their spatial crosstalk with surrounding non-tumor
cells can fundamentally improve our understanding of tumor biology, facilitates the …

Background Although immune checkpoint inhibitor (ICI) is regarded as a breakthrough in
cancer therapy, only a limited fraction of patients benefit from it. Cancer stemness can be the …

Hypoxia, as a characteristic feature of solid tumors, has a close relationship with tumor
resistance to photodynamic therapy (PDT) and chemotherapy. Perfluorocarbon (PFC) is …

Immune checkpoint blockade (ICB) therapy shows excellent efficacy against malignancies;
however, insufficient tumor immunogenicity and the immunosuppressive tumor …

Prostate cancer is characterized by a high degree of heterogeneity, which poses a major
challenge to precision therapy and drug development. In this review, we discuss how …

Tumor immune microenvironment (TIME) regulators are promising cancer
immunotherapeutic targets. IGF2BP1, as a crucial N 6-methyladenosine (m6A) reader …

Immune escape is a hallmark of cancer. The dynamic and heterogeneous tumour
microenvironment (TME) causes insufficient infiltration and poor efficacy of natural killer (NK) …